Nandrolone Decanoate
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
Conditionally bullish but high-management anabolic: nandrolone decanoate is mainly used for joint relief, collagen/connective-tissue support, slower lean-mass gain, strength, and erythropoiesis.
High-tax suppressive 19-nor AAS: do not run without a testosterone base, do not run above a 1:1 nandrolone:testosterone ratio without specialist-level monitoring, and do not treat joint relief as proof the connective tissue is ready for unlimited load.
Conditionally bullish but high-management anabolic: nandrolone decanoate is mainly used for joint relief, collagen/connective-tissue support, slower lean-mass gain, strength, and erythropoiesis. Its best fit is not a first cycle; it is a testosterone-based protocol add-on for users who can run bloodwork, manage prolactin/lipids, and tolerate a long ester.
The article's risk center is not liver toxicity; it is endocrine and cardiometabolic management. Sexual dysfunction can come from DHN replacing DHT in penile tissue, prolactin elevation, dopamine/reward-circuit effects, and full HPG shutdown. HDL suppression is documented even at lower adjunct doses, recovery is slow because the decanoate ester lingers, and women face androgenic virilization risk with no longevity-use case.
One of the most established injectable AAS options when the goal is a testosterone-based lean bulk or joint-support protocol. The value is the unusual blend of anabolic effect plus connective-tissue/joint benefit, but that value only survives when the user budgets for testosterone co-administration, prolactin and lipid labs, post-cycle timing, and conservative loading.
Very high for joint comfort and training tolerance, moderate-high for lean mass, and slower than wet mass builders. Experienced consensus is favorable but bounded: nandrolone works, especially for joints, but the long ester, prolactin/lipid burden, suppression, and testosterone-ratio discipline make sloppy use disproportionately punishing.
Do not stack with trenbolone or another 19-nor burden, do not combine with a zero-testosterone protocol, and do not add it to already poor HDL, high hematocrit, uncontrolled prolactin, fertility pressure, or female-use contexts.
Intro
Nandrolone decanoate (Deca-Durabolin) is one of the most widely used injectable anabolic-androgenic steroids, with a documented history from 1962 when Organon introduced the pharmaceutical product.
Structurally a 19-nortestosterone — testosterone with the 19th carbon removed — nandrolone binds the androgen receptor approximately 2.4-fold more potently than testosterone in vitro yet carries a dramatically lower androgenic tissue footprint in DHT-sensitive organs because it reduces to dihydronandrolone (DHN) rather than DHT. DHN is a weak androgen, producing the favorable anabolic-to-androgenic ratio of roughly 125:37 versus testosterone's 100:100 baseline. The decanoate ester provides a half-life of approximately 6–12 days, enabling once-weekly injection schedules. Pharmaceutical preparations run 100 mg/mL in Arachis oil; unregulated preparations are often described at higher concentrations. Clinically, nandrolone has been used for HIV wasting disease (+5–8 kg lean mass over 12 weeks in RCT data), osteoporosis, anemia, and post-surgical muscle preservation. Its Schedule III DEA classification limits medical access. Critically, nandrolone is invisible on standard testosterone immunoassays — a property relevant for clinical bloodwork interpretation during concurrent use. The compound is an ABSOLUTE rule: never run without testosterone co-administration. The DHN conversion in penile tissue eliminates the DHT signal required for erection, causing severe sexual dysfunction unless exogenous testosterone provides adequate DHT.
Observed Effects
Primary effects: Joint lubrication and pain reduction — among the most consistently reported practical benefits, onset 3–6 weeks; mechanism multi-factorial (collagen synthesis, progestin receptor on synovial fluid, 20% aromatization estrogenic contribution). Lean muscle mass accrual — slower and denser than testosterone-only gains; described as 'quality over quantity' vs. faster-but-wetter mass from testosterone or Dianabol. Collagen synthesis upregulation — Tatem et al. documented significant increases in type I collagen synthesis in anterior cruciate ligament cells at physiologic nandrolone concentrations. Strength gains — progressive, appearing at weeks 4–6, well retained post-cycle relative to water-retained gains. Erythropoiesis enhancement via EPO stimulation — improved red blood cell count contributes to endurance capacity and recovery. Secondary effects: IGF-1 elevation contributing to anabolism beyond direct AR binding. Nitrogen retention improvement supporting positive protein balance. Progestin-mediated joint effects — progesterone receptor binding may compensate for sub-optimal estrogen in joint fluid, explaining joint benefit even in drier hormonal environments. Tendon strengthening — climbing community data suggests load-bearing tendon remodeling beyond the synovial fluid benefit, consistent with collagen synthesis data. Hair and skin improvement in Deca-base TRT protocols — DHN replacing DHT in androgen-sensitive scalp tissue reduces hair loss relative to testosterone-equivalent protocols. Signal strength: joint benefit very strong (clinical + community + corpus convergence), muscle mass strong (clinical RCT + community consensus), collagen synthesis strong (Tatem et al. + community), erythropoiesis established pharmacology, strength moderate-strong.
Field Reports
Typical experiences: Joint pain relief appearing at weeks 3–5, often described as the primary reason users return to nandrolone cycle after cycle despite the management complexity.
Slow, dense mass accumulation described as 'keepable' gains compared to testosterone-only cycles where water/glycogen-related mass disappears post-cycle. Libido and erection issues in users who run nandrolone:testosterone ratios above 1:1 or who fail to manage prolactin — 'Deca dick' is commonly encountered in first-time users who skip bloodwork monitoring. Bloodwork surprises: prolactin elevation (>35 ng/mL documented in one case log) in users who assumed moderate doses were safe without monitoring; HDL drops more significant than expected even at TRT-adjunct doses. Positive reports: TRT clinic patients on 60 mg/week nandrolone + 100 mg/week testosterone documenting joint relief, improved body composition, and quality of life; monitored low-dose adjunct protocols have accumulated substantial positive experience. Competitive bodybuilders describing Test/Deca/Masteron at conservative individual doses as providing excellent lean-bulk results with manageable side effects. Athletes with chronic joint injuries reporting nandrolone is the only compound that provides meaningful relief — enabling training that was previously impossible. Hair-loss-sensitive users on Deca-base TRT reporting improved scalp hair retention compared to testosterone-dominant protocols. Negative reports: Users who ran nandrolone:testosterone ratios above 1:1 and experienced severe ED and libido loss — sometimes persisting weeks post-cycle. Users who experienced prolactin-driven gynecomastia and sexual dysfunction without bloodwork monitoring. Lipid impact at even modest TRT-adjunct doses being more significant than anticipated. Psychiatric symptoms and low mood during PCT after long nandrolone cycles attributed to deep HPG suppression and slower recovery than testosterone-only. First-person highlights include a canonical positive low-dose TRT-adjunct log capturing the joint and body-composition transformation, a documented Deca-only HRT experiment with extensive bloodwork confirming sexual dysfunction onset and the testosterone co-administration requirement, and a 2-month monitored protocol log with full bloodwork at 60 mg nandrolone + 100 mg testosterone weekly.
Community Consensus
Nandrolone decanoate has one of the clearest field reputations in enhanced-use communities: it is loved for joint comfort and slower, denser lean-mass gain, and feared for sexual dysfunction when users ignore the testosterone base, prolactin, estrogen context, or long-ester recovery timing. The community verdict is not mixed in the sense of uncertain efficacy; it is conditionally favorable with hard execution boundaries. Three use patterns dominate: classical Test/Deca/Dbol bulks, low-dose TRT-adjunct joint-support use around 50–100 mg/week, and hair-sensitive deca-base experiments that try to lower DHT exposure while keeping enough testosterone for libido and estrogen support. The durable debates are practical rather than theoretical: whether the 1:1 testosterone:nandrolone ratio is always necessary, whether cabergoline should be reactive rather than prophylactic, how much of the joint effect is collagen versus synovial-fluid comfort, whether boldenone is a cleaner lean-bulk alternative, and whether deca-base protocols are worth the libido/recovery complexity. Community rating: Grade A for joint comfort, Grade B-plus for lean mass, and Grade C or worse when testosterone co-administration and bloodwork are absent.
Risks & Monitoring
Primary adverse effect: Sexual dysfunction ('Deca dick') — multi-root-cause: (1) DHN replacement of DHT in penile tissue removes the nitric oxide/erection signal; (2) Prolactin elevation from progestin receptor signaling — community logs show prolactin >35 ng/mL in unmanaged users; (3) Dopamine D2 receptor downregulation from chronic nandrolone (Alsiö et al. 2009) blunts libido at CNS level; (4) Deep HPG suppression eliminates endogenous testosterone. Fully preventable with adequate testosterone co-administration + cabergoline if prolactin rises. Onset typically weeks 6–12. Prolactin elevation — progestin receptor activity sensitizes lactotroph cells; clinical galactorrhea has been documented; manageable with cabergoline 0.25–0.5 mg twice weekly. HDL cholesterol suppression — 60 mg/week TRT-adjunct dose reduced HDL from 55 to 40 mg/dL in one log; RCT data shows 15–26% HDL reduction. Deep HPG axis suppression — 19-nor compounds are among the most suppressive for the HPA axis; recovery slower than testosterone-only cycles. Secondary: Carrier oil (Arachis/peanut) CRP elevation — pharmaceutical Deca-Durabolin uses Arachis oil; one experiment showed hsCRP rise of 94.4% within 48 hours from the carrier, not nandrolone itself. Psychiatric and withdrawal effects documented in clinical literature; abrupt cessation can trigger depression. Androgenic effects (hair loss, acne) significantly lower than testosterone due to DHN not DHT — this is nandrolone's primary safety advantage for androgen-sensitive tissues. Opioid receptor downregulation (Alsiö et al. 2009) contributes to anhedonia at high doses. Not observed: hepatotoxicity (nandrolone is not 17-alpha-alkylated); estrogenic gynecomastia at standard doses (20% aromatization rate is substantially lower than testosterone).
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Establishes pre-cycle endogenous baseline; essential for detecting HPG suppression and confirming adequate exogenous testosterone compensates during cycle. Nandrolone is invisible on standard testosterone immunoassays — values during nandrolone use reflect only co-administered testosterone.
Prolactin elevation is the key manageable driver of sexual dysfunction. Midcycle check at weeks 6–8 catches elevation before it becomes symptomatic. Target: keep prolactin within reference range (<18–20 ng/mL). If elevated, cabergoline 0.25–0.5 mg twice weekly resolves in most cases.
HDL suppression of 15–26% at therapeutic doses documented; 60 mg/week dropped HDL from 55 to 40 mg/dL in one case. Monitor at baseline and 6–8 weeks. Adjust or discontinue if HDL drops below 35 mg/dL.
Nandrolone stimulates erythropoiesis via EPO; hematocrit elevation increases blood viscosity and cardiovascular risk. Particularly important at higher doses or longer cycles.
Kidney function baseline, liver enzymes, electrolytes. Nandrolone is non-hepatotoxic but CMP provides full metabolic context. Baseline ALT/AST allows attribution if other compounds are co-administered.
Nandrolone aromatizes at 20% of testosterone's rate — relevant for managing gynecomastia and joint fluid status. Low E2 worsens joint dryness; high E2 in context of elevated prolactin can amplify lactotroph sensitization. Target mid-range E2.
HPG axis recovery assessment 3–6 weeks post-last-injection (accounting for long decanoate ester half-life). LH and FSH returning toward reference range confirms pituitary recovery. PCT should not begin until nandrolone has substantially cleared — typically 3 weeks post-injection.
Particularly relevant for pharmaceutical Deca-Durabolin users: Arachis oil carrier caused a 94.4% hsCRP rise in one N=1 experiment unrelated to nandrolone itself. Baseline hsCRP allows correct attribution of inflammatory signal to carrier vs. nandrolone pharmacology.
Avoid With
Do not combine Nandrolone Decanoate with the following. Sorted highest-severity first.
Why:Both compounds are progestins and share dopamine D2 receptor downregulation mechanisms. Running two 19-nor compounds together dramatically increases prolactin, progesterone receptor-driven side effects, and sexual dysfunction risk. Trenbolone + Nandrolone is a particularly problematic combination.
What to do:NPP (nandrolone phenylpropionate) vs Nandrolone Decanoate is the same molecule different esters — switching between them is fine, but stacking them compounds the same 19-nor side effect burden.
Why:Running nandrolone without co-administered testosterone eliminates exogenous DHT precursor and amplifies all DHN-related sexual dysfunction. This is the primary cause of 'Deca dick'. Empirically confirmed in a documented Deca-only HRT experiment — severe sexual dysfunction requiring discontinuation.
What to do:Even at TRT-adjunct doses, the testosterone component must be maintained at sufficient level to preserve DHT and libido. The minimum effective testosterone co-dose is typically 100 mg/week; lower may be insufficient.
Why:In the presence of elevated estrogen, nandrolone's progestin receptor activity can synergize with estrogen to increase prolactin sensitivity and gynecomastia risk beyond what either compound causes alone. The progestin+estrogen combination amplifies lactotroph response.
What to do:Estrogen management (not aggressive suppression — keep E2 in mid-range) reduces this interaction. Prolactin monitoring catches the combination effect early.
Why:Organon Deca-Durabolin uses Arachis (peanut-derived) oil. Documented 94.4% hsCRP rise from carrier injection in one experiment — the inflammatory response was from the carrier, not nandrolone. Peanut-allergic individuals are at risk.
What to do:unregulated supply preparations using Miglyol or other carrier oils may be preferable for individuals with peanut sensitivity or unexplained CRP elevation on pharmaceutical Deca.
Protocols By Goal
Lean Bulk: Nandrolone Decanoate 300–400 mg/week + Testosterone Enanthate/Cypionate 400–500 mg/week, 14–16 weeks.
Optional Dianabol kickstart 25–40 mg/day weeks 1–4 to bridge nandrolone's slow buildup. AI if estrogen symptomatic. Cabergoline 0.25–0.5 mg twice weekly if prolactin rises at weeks 6–8. PCT 3 weeks post-last-injection. Community consensus 'gold standard' bulk — slower but denser gains than testosterone-only. Expect strength onset weeks 4–6, joint benefits weeks 3–5. | TRT Adjunct / Joint Support: Nandrolone Decanoate 50–100 mg/week added to existing TRT protocol (100–200 mg/week testosterone). Monitor prolactin at baseline and 6–8 weeks. Monitor lipids at 8 weeks. A commonly cited monitored protocol uses 60 mg nandrolone + 100 mg testosterone. Not a 'cycle' — intended as long-term TRT enhancement. At this dose joint relief is often dramatic for chronic joint pain patients. | Joint Recovery / Connective Tissue Healing: Nandrolone Decanoate 100–200 mg/week with Testosterone at minimum 200 mg/week. Often combined with BPC-157 for additive collagen support. Minimum 12 weeks for collagen remodeling benefits. 50 mg/week nandrolone combined with 156 mg testosterone and 125 mg primobolan weekly has been reported for knee pain resolution. | Nandrolone-base TRT (hair-sensitive protocol): Nandrolone Decanoate 100–200 mg/week as primary androgen with low-dose Testosterone 50–100 mg/week to maintain DHT and libido. Estrogen monitoring critical — nandrolone provides less aromatization than full testosterone doses. Note: Deca-only (zero testosterone) has been empirically shown to cause severe sexual dysfunction — the Deca-base concept requires enough testosterone to maintain adequate DHT, not zero.
Dosing Details
Dose range: therapeutic/TRT-adjunct 50–100 mg/week, conservative bodybuilding 200–300 mg/week, standard bodybuilding 300–400 mg/week, advanced/competitive 400–600 mg/week.
The iron rule: testosterone must be co-administered at equal or greater dose at all times. The nandrolone:testosterone ratio must never exceed 1:1. Frequency: once-weekly injection is standard given the 6–12 day half-life; every 5–7 days provides marginally smoother blood levels. Subcutaneous micro-dosing has been explored at TRT-adjunct doses in the community. Cycle length: 12–16 weeks minimum to see full benefit — the decanoate ester takes several weeks to reach stable levels. PCT timing: begin 3 weeks post-last-injection to allow ester clearance before SERM therapy. Cabergoline 0.25–0.5 mg twice weekly should be available and initiated if prolactin exceeds reference range at weeks 6–8 bloodwork check. Documented TRT-adjunct protocols use about 60 mg nandrolone + 100 mg testosterone weekly — primary goals are joint support and body composition rather than significant mass gain at this dose.
Stacks & Alternatives
Non-negotiable co-administration. Testosterone provides DHT for sexual function, additional estrogen for joint fluid, and maintains androgen balance nandrolone alone cannot provide. The 1:1 or higher testosterone:nandrolone ratio rule is a hard community guideline — universal consensus, mechanistically supported by DHN vs DHT conversion.
Dopamine agonist for prolactin control. Standard prophylactic or reactive dose: 0.25–0.5 mg twice weekly. Dramatically reduces 'Deca dick' incidence when prolactin is the primary driver. Not universally required — many users with adequate testosterone co-administration never develop problematic prolactin elevation — but should be available and used if bloodwork shows elevation.
Additive to nandrolone's collagen and tendon benefits. BPC-157's growth factor upregulation and local tissue healing complement nandrolone's systemic collagen synthesis and joint lubrication. Community uses this combination specifically for chronic injury rehabilitation where both systemic and local healing mechanisms are desired.
Kickstart compound — Dianabol oral weeks 1–4 bridges the slow buildup of nandrolone's decanoate ester, providing rapid strength and mass gains while nandrolone reaches stable levels. Classic Test/Deca/Dbol is one of the most historically popular bulk cycles in bodybuilding.
Low-androgenic, moderate anabolic companion; sometimes substituted for higher testosterone to maintain androgen balance while managing androgenic side effects. Test/Deca/Primo at lower individual doses reported for joint and body composition benefits with lower androgenic burden. 50 mg nandrolone + 156 mg testosterone + 125 mg Primo weekly documented for knee pain resolution.
Aesthetic hardening compound; added to Test/Deca cycles to offset estrogenic softness and improve muscle definition. One documented log: 200 mg testosterone + 150 mg nandrolone + 200 mg Masteron for lean bulk/body recomposition with positive outcome.
Alternatives
Stack Cost
High stack tax: nandrolone decanoate can be valuable for joints and lean mass, but it spends HPG-axis, prolactin, lipid, hematocrit, fertility, injection, and long-ester recovery capacity.
The article repeatedly frames nandrolone as deeply suppressive, requires a testosterone base, and delays PCT until roughly 3 weeks after the last decanoate injection.
The article identifies HDL suppression of 15–26% in RCT data and an HDL drop from 55 to 40 mg/dL in one lower-dose log; CBC monitoring is also relevant because nandrolone stimulates erythropoiesis.
Progestin receptor activity, prolactin sensitivity, lower DHT conversion, and the testosterone:nandrolone ratio all need active management to prevent sexual dysfunction and gynecomastia-like failure modes.
The compound is suppressive, long-acting, inappropriate for women, and poorly matched to near-term fertility goals because recovery timing is slower than testosterone-only exposure.
Weekly injection is manageable, but the decanoate ester removes the quick-exit option; bad side effects or overexposure cannot be corrected as quickly as with NPP.
- ·Counts as a full suppressive AAS lane, not as a mild joint supplement.
- ·Requires a testosterone base; zero-testosterone nandrolone is a hard failure pattern in the article.
- ·Do not stack with trenbolone or another 19-nor burden because prolactin, progestin, libido, and CNS/reward effects compound.
- ·Budget lipid and prolactin capacity before adding oral AAS, high-dose aromatizing androgens, or other compounds that worsen blood pressure, HDL, estrogen, or hematocrit.
- ·For injury use, joint comfort should not be treated as permission to overload tissue before remodeling and rehab capacity catch up.
- ·Testosterone-base planning and estrogen interpretation
- ·Baseline and midcycle prolactin, lipid panel, CBC, testosterone, estradiol, and post-cycle LH/FSH follow-up
- ·Cabergoline access if prolactin rises rather than blind prophylaxis
- ·Long-ester off-ramp and PCT timing
- ·Female-use exclusion and fertility timing caution
Ordinary misuse can cause serious endocrine, sexual, lipid, fertility, and recovery problems. The article requires prior testosterone response knowledge, bloodwork literacy, and long-ester planning.
- ·First AAS cycle
- ·No testosterone base
- ·No prolactin or lipid testing
- ·Female user seeking longevity/recovery/cosmetic benefit
- ·Near-term fertility plans
The decanoate ester clears slowly, so side effects and suppression can persist for weeks after the final injection; PCT timing is delayed rather than immediate.
Practical Setup
Who should consider: Intermediate-to-advanced AAS users who have already established their testosterone response and want to add joint support and lean mass.
TRT patients with chronic joint pain who have access to prescribing practitioners comfortable with monitored adjunct use. Athletes with connective tissue injuries where collagen synthesis support is the primary goal. Who should avoid: Beginners — nandrolone adds complexity (prolactin management, carrier oil, long ester PCT timing, testosterone ratio discipline) inappropriate for first-cycle users. Women — virilization risk from even low doses. Users who cannot or will not monitor bloodwork — nandrolone without prolactin and lipid monitoring is substantially higher risk. Users prone to depression or libido issues who cannot tolerate the learning curve. Biomarkers to track: Prolactin (most critical, midcycle at weeks 6–8); HDL/lipid panel (baseline and 6–8 weeks); Hematocrit (erythropoiesis monitoring); Estradiol Sensitive (E2); Total + Free Testosterone; LH + FSH post-cycle; hsCRP if using pharmaceutical Arachis oil formulation. Key management principles: (1) Testosterone co-administration at equal or greater dose — non-negotiable. (2) Nandrolone:testosterone ratio at or below 1:1. (3) Prolactin monitoring at weeks 6–8; cabergoline available and initiated if prolactin exceeds reference range. (4) PCT begins 3 weeks post-last-injection — account for long ester clearance before starting SERMs. (5) Lipid monitoring at 6–8 weeks; adjust or discontinue if HDL drops below 35 mg/dL. Common mistakes: Running nandrolone without testosterone or with insufficient testosterone — single most common cause of 'Deca dick'. Exceeding 1:1 nandrolone:testosterone ratio without prolactin monitoring. Expecting fast gains like Dianabol — nandrolone takes 4–6 weeks for strength effects, 6–8 weeks for full mass expression. Starting PCT too early — the long ester means nandrolone is still active 2–3 weeks after last injection. Ignoring the Arachis oil carrier in pharmaceutical Deca — unexplained CRP elevation may be carrier-related, not nandrolone-related.
Mechanism Deep Dive
Nandrolone is a 19-nortestosterone — structurally testosterone with the 19th carbon (C19) removed from the steroid backbone.
This single structural modification profoundly changes tissue-specific metabolism. In DHT-sensitive tissues (scalp, prostate, skin, penile tissue), 5-alpha reductase converts nandrolone to dihydronandrolone (DHN) rather than DHT. DHN has approximately 1/10 the androgenic potency of DHT — explaining nandrolone's dramatically reduced hair loss, prostate, and acne burden versus testosterone, but also the 'Deca dick' problem: penile erection requires DHT/nitric oxide signaling in corpus cavernosum tissue, and DHN cannot substitute. Androgen receptor binding: nandrolone binds AR approximately 2.4x more potently than testosterone in vitro, contributing to strong anabolic signaling in muscle despite lower androgenic peripheral effects (anabolic:androgenic ratio ~125:37 vs testosterone's 100:100 baseline). Progestin receptor activity: nandrolone binds progesterone receptors with meaningful affinity, adding a progestin signaling layer. This contributes to joint fluid production and collagen synthesis but also sensitizes the prolactin axis (lactotrophs) in the presence of estrogen — a dual-edged property. Aromatization: at approximately 20% of testosterone's rate at equivalent doses, providing meaningful estrogen for joint fluid, mood, and cardiovascular function, but not fully substituting for exogenous testosterone's estrogen contribution. Collagen synthesis: Tatem et al. documented increases in type I collagen synthesis in ligament cells at physiologic nandrolone concentrations — direct connective tissue remodeling separate from the lubrication/fluid mechanism. Erythropoiesis via EPO stimulation: direct effect on kidney EPO production increasing red blood cell count and hematocrit. HPG axis suppression: 19-nor compounds are among the most potent suppressors of the hypothalamic-pituitary-gonadal axis; LH and FSH drop rapidly within weeks. PDE7B ester hydrolysis mechanism: the decanoate ester is cleaved primarily by PDE7B in liver cytosol; androgen-upregulated PDE7B transcription creates mild positive feedback at higher androgen exposure. Dopamine D2 and opioid receptor downregulation: Alsiö et al. 2009 demonstrated chronic nandrolone reduces mu-opioid and D2 receptor expression in reward circuits — contributing to anhedonia and libido blunting independent of prolactin and DHT mechanisms. IGF-1 upregulation contributes to anabolic environment beyond direct AR signaling. Nitrogen retention (classical AAS intracellular mechanism) creates positive nitrogen balance supporting protein synthesis.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
Clinical use in HIV wasting produced roughly 5–8 kg lean-mass gain over 12 weeks in RCT data.
Strong human support for anabolic effect in a catabolic medical population; transfer to bodybuilding protocols is directional rather than dose-equivalent.
Tatem et al. documented increased type I collagen synthesis in anterior cruciate ligament cells at physiologic nandrolone concentrations.
Supports a connective-tissue mechanism, but does not prove faster safe return-to-load by itself.
RCT data shows 15–26% HDL reduction.
Use as a cardiometabolic direction-of-risk anchor; community bodybuilding doses and stacks may produce larger or different lipid movement.
A 60 mg/week TRT-adjunct log dropped HDL from 55 to 40 mg/dL.
Practical signal that lipid monitoring matters even below bodybuilding doses; not a population-average estimate.
Community logs show prolactin above 35 ng/mL in unmanaged users.
Supports midcycle prolactin monitoring and reactive cabergoline availability; does not prove every user needs prophylactic dopamine agonist use.
The decanoate ester provides an approximate 6–12 day half-life and supports once-weekly injection schedules.
Relevant for injection frequency, delayed PCT timing, and slower off-ramp compared with NPP.
Nandrolone binds the androgen receptor approximately 2.4-fold more potently than testosterone in vitro.
Mechanistic potency context; should not be converted directly into human dose equivalence.
A pharmaceutical Arachis oil injection experiment showed hsCRP rising 94.4% within 48 hours from the carrier rather than nandrolone itself.
Useful for attribution of inflammatory bloodwork, especially in peanut-sensitive users; not a general nandrolone inflammation estimate.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.